GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » EV-to-Revenue

Actelion (XSWX:ATLNE) EV-to-Revenue : 2.86 (As of May. 02, 2024)


View and export this data going back to . Start your Free Trial

What is Actelion EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Actelion's enterprise value is CHF7,085 Mil. Actelion's Revenue for the trailing twelve months (TTM) ended in Mar. 2017 was CHF2,475 Mil. Therefore, Actelion's EV-to-Revenue for today is 2.86.

The historical rank and industry rank for Actelion's EV-to-Revenue or its related term are showing as below:

XSWX:ATLNE' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4   Med: 5.1   Max: 11.9
Current: 2.86

During the past 13 years, the highest EV-to-Revenue of Actelion was 11.90. The lowest was 1.40. And the median was 5.10.

XSWX:ATLNE's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.82 vs XSWX:ATLNE: 2.86

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-02), Actelion's stock price is CHF65.26. Actelion's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2017 was CHF21.43. Therefore, Actelion's PS Ratio for today is 3.04.


Actelion EV-to-Revenue Historical Data

The historical data trend for Actelion's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion EV-to-Revenue Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.33 4.32 6.05 6.97 9.20

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.87 7.56 7.48 9.20 11.42

Competitive Comparison of Actelion's EV-to-Revenue

For the Biotechnology subindustry, Actelion's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actelion's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Actelion's EV-to-Revenue falls into.



Actelion EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Actelion's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=7084.770/2474.656
=2.86

Actelion's current Enterprise Value is CHF7,085 Mil.
Actelion's Revenue for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,475 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion  (XSWX:ATLNE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Actelion's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=65.26/21.433
=3.04

Actelion's share price for today is CHF65.26.
Actelion's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF21.43.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Actelion's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (XSWX:ATLNE) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines